Semaglutide Treatment in Type 1 Diabetes

Launched by NORDSJAELLANDS HOSPITAL · Mar 26, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how effective a medication called semaglutide is for people with Type 1 Diabetes who also struggle with being overweight. The study aims to see if semaglutide can help reduce body weight, lower the amount of insulin needed, and improve blood sugar control while also keeping patients safe from potential complications like low blood sugar or diabetic ketoacidosis, which is a serious condition that can occur with diabetes.

To be eligible for this trial, participants need to have had Type 1 Diabetes for at least three years and a body mass index (BMI) of 30 or higher, or a BMI of 27 or more with other health issues like high blood pressure or heart problems. The trial is currently not recruiting participants yet, but once it starts, people who qualify can expect regular visits for assessments and support as they try this new treatment. It’s important to note that certain conditions, like liver disease, pregnancy, or recent participation in other clinical studies, could prevent someone from joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Type 1 Diabetes for more than 3 years
• • BMI ≥ 30 or ≥ 27 and atleast one comorbidity (hypertension, hypercholesterolemia, microalbuminuria, ischemic heart disease, history of stroke, atherosclerosis or arthrosis
• Exclusion Criteria:
• • Treated with GLP1-RAs within last 6 months
• • Known intolerance for semaglutide
• • Other forms of diabetes
• • Pregnant or nursing women
• • Fertile women not using chemical (hormonal) or mechanical (spiral) contraceptives
• • Liver disease with elevated plasma alanine aminotransferase (ALT) \> five times and plasma aspartate aminotransferase (AST) \> five times the upper limit of normal (measured at visit 0 with the possibility of one repeat analysis within a week, and the last measured value as being conclusive)
• • Acute or chronic pancreatitis
• • Cancer, unless in complete remission for \> 5 years or unless basocellular carcinomas
• • History of thyroid adenoma or carcinoma
• • Alcohol/drug abuse
• • Other concomitant disease or treatment that according to the investigator's assessment makes the patient unsuitable for study participation
• • Receipt of an investigational drug within 30 days prior to visit 0 / Simultaneous participation in any other clinical intervention trial